Publications & Presentations

Vectra Da

Publications & Presentations

A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure.

Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the AMPLEstudy: Comment on the article by Fleischmann et al.

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.

The use of a multi-biomarker disease activity score as an inclusion criterion in rheumatoid arthritis clinical trials may enhance patient recruitment.

A multi-biomarker disease activity score for monitoring rheumatoid arthritis

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.

Relationship of multi-biomarker disease activity score and other risk factors

Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis

©2017 Crescendo Bioscience, Inc. All rights reserved. Vectra, Crescendo Bioscience, MyRA and the associated logos are trademarks or registered trademarks of Crescendo Bioscience, Inc. in the United States and other jurisdictions.